CJC-1295 with DAC
Long-acting GHRH analog
A GHRH analog with a drug affinity complex that extends half-life to roughly one week.
How it works
The DAC moiety binds serum albumin, protecting the peptide from enzymatic clearance and producing a sustained elevation in GH and IGF-1 rather than discrete pulses.
What research has shown
Human studies report GH increases of 2 to 10 fold and IGF-1 increases of 1.5 to 3 fold sustained for 6 or more days after a single dose.
Reported ranges in the literature
Low end
1 mg weekly
Optimal
2 mg weekly
High end
2 mg twice weekly in reported protocols
Frequency reported in the literature: Once or twice weekly. Note: The sustained profile differs from the pulsatile pattern of the no-DAC version.
Protocol duration and pairing
Typical study duration
8 to 16 weeks; the DAC extension means weekly rather than daily administration in reported schedules.
Best paired with
Long half-life creates a raised GH baseline that pairs with a short-acting GHRP for pulses.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.